This clinical trial is to determine the safety, tolerability, pharmacokinetics, and efficacy of AMG 160 in men with metastatic castration-resistant prostate cancer (mCRPC).
Why is this study being done?
This study involves evaluating the safety and tolerability of an investigational medication, AMG 160, in adult subjects with mCRPC and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). Subjects should have failed a novel antiandrogen therapy (abiraterone, enzalutamide, and/or apalutamide) and have failed at least 1 (but not more than 2) taxane treatments
The treatments being studied:
This is a phase I, first-in-human study to evaluate the safety and tolerability of AMG 160, a half-life extended (HLE) bispecific T-cell engager (BiTE®) antibody, in subjects with metastatic castration-resistant prostate cancer. AMG 160 is a type of immunotherapy, which may help the body’s immune system attack cancer cells.
Before deciding to participate, you should make sure you understand the potential side effects or risks of participating in the study. These will be explained to you by the study doctor. If there is anything you do not understand, you are encouraged to ask the study doctor.
If you are interested in this trial, review the following:
PHEN Contact: 617-481-4020
Please Note: This information is provided for education and awareness purposes. A decision on clinical trials participation is to be made between the patient and his doctor